Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

ABT Eyes Q3 Beat and CardioMEMS Update as Near-Term Catalyst

Oct 19, 2026, 7:52 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Beat expectations paired with a regulatory upgrade in CardioMEMS creates a favorable near-term setup; multiple bullish analyst calls support upside potential.

AI summary

What happened, with direct paths to the underlying reporting

Abbott reports Q3 earnings on Oct 21 before the open, with consensus $1.41 per share on $12.99 billion revenue. The Oct 5 FDA approval for CardioMEMS HF System updates, including the CardioGuide HF App, could lift the device portfolio and drive growth expectations. With bullish analyst sentiment and higher price targets, ABT may rally on a stronger-than-expected print and regulatory upside.

ABT Q3 earnings due Oct 21 before market; street expects $1.41, $12.99B.
FDA approved CardioMEMS HF System updates on Oct 5, includes CardioGuide HF App.
ABT stock closed at $104.89, up 0.2% on Friday.
Analysts publish Buy/Overweight with targets up to $135.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

ABT Eyes Q3 Beat and CardioMEMS Update as Near-Term Catalyst

Barclays starts ABT coverage with Overweight and $120 target

Abbott Laboratories Upgraded to Buy with Higher Target by Rothschild & Co

Abbott to pay over $384 million to settle infant formula allegations

Abbott's Libre Duo 10 Day FDA approval sets ABT up for near-term upside